Counterpoint
08/22/2018
Chadi Nabhan, MD, MBA, FACP; Bruce A. Feinberg, DO
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The commercial success and ability of eligible patients to receive chimeric antigen receptor T-cell (CAR-T) therapies depend on optimizing the logistics of delivering this transformational treatment platform. One...
The...
08/22/2018
Journal of Clinical Pathways